Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Overall Survival
89%
Netherlands
65%
Population-based Cohort Study
61%
R-CHOP
53%
Autologous Stem Cell Transplantation (auto-SCT)
52%
Peripheral T-cell Lymphoma
51%
Chemotherapy
44%
Netherlands Cancer Registry
39%
Lymphoma Patients
32%
Progression-free Survival
32%
Patient Outcomes
27%
Treatment Strategy
26%
Salvage Chemotherapy
24%
Anaplastic Large Cell Lymphoma
24%
Diffuse Large B-cell Lymphoma (DLBCL)
23%
National Cohort Study
23%
Complete Remission
23%
5-year Survival
22%
Clinical Characteristics
20%
Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
20%
Brentuximab Vedotin
20%
Treatment Outcome
20%
Primary Central Nervous System Lymphoma (PCNSL)
20%
High-dose Methotrexate (HD-MTX)
20%
Survival Outcomes
20%
Polytherapy
20%
Clinical Survival
20%
Consolidation Therapy
20%
Enteropathy-associated T-cell Lymphoma
20%
Atezolizumab
20%
High Risk
20%
Primary Testicular Lymphoma
20%
Rituximab Maintenance
20%
Mantle Cell Lymphoma
20%
Multiple Myeloma
20%
Real-world Outcomes
20%
High-dose Melphalan
20%
Angioimmunoblastic T-cell Lymphoma
20%
Combined Modality Therapy
20%
Ara-C
17%
Etoposide
17%
Hazard Ratio
17%
High-dose Chemotherapy
17%
Treatment Lines
16%
95% Confidence Interval
15%
Second-line Treatment
15%
Relapse Risk
12%
Peripheral T-cell lymphoma-NOS
12%
Disease-free Survival
12%
Metabolic Remission
12%
Medicine and Dentistry
Overall Survival
100%
Chemotherapy
75%
Cohort Analysis
61%
Peripheral T-Cell Lymphoma
49%
Autologous Stem Cell Transplantation
43%
Anaplastic Large Cell Lymphoma
43%
Drug Megadose
41%
Progression Free Survival
36%
Cancer Registry
36%
Diffuse Large B-Cell Lymphoma
24%
Diseases
21%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Methotrexate
20%
Breast Implant
20%
MALT Lymphoma
20%
Brentuximab Vedotin
20%
Combination Chemotherapy
20%
Primary Central Nervous System Lymphoma
20%
Enteropathy-Associated T-Cell Lymphoma
20%
Atezolizumab
20%
Multiple Myeloma
20%
Melphalan
20%
Treatment Modality
20%
Angioimmunoblastic T-Cell Lymphoma
18%
Radiation Therapy
17%
High Dose Chemotherapy
17%
Etoposide
14%
CHOP
12%
Hazard Ratio
12%
Disease Free Survival
12%
Quality of Life
10%
Carmustine
9%
Lactate Dehydrogenase
8%
Allogeneic Stem Cell Transplantation
8%
Anaplastic Lymphoma Kinase
8%
International Prognostic Index
8%
Whole Brain Radiotherapy
6%
Rituximab
6%
